General Information
Perampanel, a first-in-class substance (a non-competitive AMPA receptor antagonist), is used to treat patients with epilepsy aged 12 and older. Specifically, it is used as adjunctive therapy for partial onset seizures (with or without secondarily generalized seizures) and primary generalized tonic-clonic (PGTC) seizures.
About the API
Technology
Synthetic
Therapeutic category
Neurology-Psychiatry
Available formulations
Oral Liquid
Oral Solid
Regulations
US DMF
US DMF